Agios Pharma (AGIO) Tops Q3 EPS by $1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. SPY
10. KNX

Go back to Agios Pharma (AGIO) Tops Q3 EPS by $1

Agios Reports Business Highlights and Third Quarter 2024 Financial Results

October 31, 2024 6:30 AM EDT

Completed Enrollment of the Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease; Topline Data from 52-Week Study Expected in Late 2025

Received $1.1 Billion in Payments from Royalty Pharma and Servier, Following FDA Approval
of Vorasidenib

Commenced Enrollment of the Phase 2b Study of Tebapivat in Lower-Risk Myelodysplastic Syndromes (LR-MDS); Granted FDA Orphan Drug Designation for Treatment of MDS

PYRUKYND® (Mitapivat) Net Revenue of $9.0 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $1.7 Billion as of September 30, 2024

CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE... More